ストックスクリーナーアプリを入手
0.00
100.00%
-2.05
アフターアワーズ：
2.06
2.06
+
前日終値:
$2.05
開ける：
$0
24時間の取引高:
0
Relative Volume:
0.00
時価総額：
$94.89M
収益：
$23.26M
当期純損益:
$-63.41M
株価収益率:
0.00
EPS:
-2.36
ネットキャッシュフロー:
$-64.56M
1週間 パフォーマンス:
-100.00%
1か月 パフォーマンス:
-100.00%
6か月 パフォーマンス:
-100.00%
1年 パフォーマンス:
-100.00%
1日の値動き範囲:
$0.00
$0.00
1週間の範囲:
$0.00
$0.00
52週間の値動き範囲:
$0.00
$3.812
Aadi Bioscience Inc Stock (AADI) Company Profile
名前
Aadi Bioscience Inc
セクター
電話
424-473-8055
住所
17383 SUNSET AVENUE, PACIFIC PALISADES
AADI を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AADI
Aadi Bioscience Inc
|
0.00 | 94.89M | 23.26M | -63.41M | -64.56M | -2.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Aadi Bioscience Inc Stock (AADI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-27 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2024-08-21 | ダウングレード | Jefferies | Buy → Hold |
| 2024-08-21 | ダウングレード | TD Cowen | Buy → Hold |
| 2023-12-15 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2022-01-11 | 開始されました | Jefferies | Buy |
| 2021-10-01 | 開始されました | Cowen | Outperform |
| 2021-09-14 | 開始されました | Ladenburg Thalmann | Buy |
| 2021-09-08 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Aadi Bioscience Inc (AADI) 最新ニュース
Two Sigma Investments LP Buys 51,638 Shares of Aadi Bioscience, Inc. (NASDAQ:AADI) - Defense World
Aadi Bioscience Grants New CEO Dave Lennon, Ph.D. Inducement Award Under Nasdaq Listing Rule 5635 (c)(4) - The Globe and Mail
Two Sigma Advisers LP Boosts Stock Position in Aadi Bioscience, Inc. (NASDAQ:AADI) - Defense World
Northern Trust Corp Grows Stake in Aadi Bioscience, Inc. (NASDAQ:AADI) - Defense World
Aadi Bioscience to Present at Upcoming Investor Conferences - marketscreener.com
Reviewing Aadi Bioscience (NASDAQ:AADI) & UCB (OTCMKTS:UCBJF) - Defense World
Whitehawk Therapeutics Reports Strong Q1 2025 Results - TipRanks
Whitehawk Reports First Quarter 2025 Financial Results and Recent Highlights - PR Newswire
Geode Capital Management LLC Purchases 8,546 Shares of Aadi Bioscience, Inc. (NASDAQ:AADI) - Defense World
Aadi Bioscience (NASDAQ:AADI) Trading Down 0.6% – Should You Sell? - Defense World
Ten March deals passed $1B, totaling $25.31B in value - BioWorld MedTech
Personalized Medicine Market Forecast Report and Company Analysis 2025-2033 Featuring Abbott, GE, Aadi Bioscience, Illumina, QIAGEN, Eli Lilly and Co, Takeda, AbbVie, F. Hoffmann-La RocheResearchAndMarkets.com | FinancialContent - FinancialContent
Analyzing Aadi Bioscience (NASDAQ:AADI) and Orgenesis (NASDAQ:ORGS) - Defense World
Whitehawk Therapeutics - The Pharma Letter
Aadi Bioscience Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations - MarketScreener
Aadi Bioscience to Participate at Upcoming Investor Conferences - MarketScreener
Aadi Bioscience to Participate in Upcoming Investor Events - MarketScreener
Aadi Bioscience Announces Poster Presentations at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - MarketScreener
Aadi Bioscience Announces Poster Presentations on Nab-Sirolimus at the International Gynecologic Cancer Society (IGCS) 2023 Annual Global Meeting - MarketScreener
Aadi Bioscience to Present at the TD Cowen 44th Annual Healthcare Conference - MarketScreener
Aadi Bioscience, Inc. Announces First Patient Dosed in its PRECISION 1 Phase 2 Registrational Trial of nab-Sirolimus in Patients with Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 Genes - MarketScreener
Earnings Flash (AADI) AADI BIOSCIENCE Posts Q4 Revenue $5.2M - MarketScreener
Aadi Bioscience, (AADI) reports earnings - Quartz
Whitehawk Therapeutics Closes Sale of Aadi Subsidiary to Kaken Pharmaceuticals - citybiz
Whitehawk Therapeutics sells subsidiary for $102.4 million - Investing.com Australia
Whitehawk Therapeutics sells subsidiary for $102.4 million By Investing.com - Investing.com Canada
Whitehawk sells Aadi Subsidiary to Kaken for $100 million - Investing.com
Whitehawk sells Aadi Subsidiary to Kaken for $100 million By Investing.com - Investing.com India
Whitehawk Therapeutics Completes Strategic Transformation With Successful Closing Of Sale Of Aadi Subsidiary To Kaken Pharmaceuticals - Marketscreener.com
Whitehawk Therapeutics Completes Strategic Transformation with Successful Closing of Sale of Aadi Subsidiary to Kaken Pharmaceuticals - The Victoria Advocate
Aadi Bioscience Announces $72.5 Million Private Placement Equity Financing - MarketScreener
Aadi Bioscience Announces Participation in Upcoming September Investor Conferences - MarketScreener
Aadi Bioscience Announces Leadership Transition - MarketScreener
Aadi Bioscience Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-sirolimus at the 34th EORTC-NCI-AACR Symposium - MarketScreener
Aadi Bioscience, Inc. (NASDAQ:AADI) Q4 2024 Earnings Call Transcript - Insider Monkey
Aadi Bioscience’s Earnings Call: Strategic Shifts and Promising Pipeline - TipRanks
Suvretta Capital Management, LLC Acquires Significant Stake in A - GuruFocus
Aadi Bioscience Announces Approval of All Proposals at Special M - GuruFocus.com
Aadi Bioscience, Inc. Appoints Baiteng Zhao to its Board of Directors - MarketScreener
Aadi Bioscience Announces Financial Results for the First Quarter 2024 and Provides Corporate Update - Marketscreener.com
Aadi Bioscience Announces Financial Results for the Second Quarter 2024 and Provides Corporate Update - Marketscreener.com
HC Wainwright Adjusts Price Target on Aadi Bioscience to $45 From $48, Maintains Buy Rating - MarketScreener
Aadi Bioscience, Inc. Announces CEO Changes - MarketScreener
Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO) - Marketscreener.com
Aadi Bioscience to Participate in the Jefferies Healthcare Conference - MarketScreener
Aadi Bioscience Announces Approval of All Proposals at Special Meeting of Stockholders - Marketscreener.com
Aadi Bioscience Inc (AADI) Q4 2024 Earnings Call Highlights: Strategic Transition and Financial ... By GuruFocus - Investing.com Canada
Whitehawk Therapeutics: Strategic Shift and Financial Outlook - TipRanks
Aadi rebrands as Whitehawk Therapeutics in new ADC focus - The Pharma Letter
Aadi Bioscience, Inc. will Change its Name to Whitehawk Therapeutics, Inc -March 19, 2025 at 12:00 am EDT - Marketscreener.com
Aadi Bioscience earnings missed by $0.46, revenue fell short of estimates - Investing.com UK
Aadi Bioscience Inc (AADI) 財務データ
収益
当期純利益
現金流量
EPS
Aadi Bioscience Inc (AADI) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Giacobello Scott M. | CHIEF FINANCIAL OFFICER |
Mar 03 '25 |
Sale |
2.35 |
2,806 |
6,594 |
23,944 |
| Lennon David James | CHIEF EXECUTIVE OFFICER |
Mar 03 '25 |
Sale |
2.35 |
5,690 |
13,372 |
33,429 |
0.68%
0.50%
大文字化:
|
ボリューム (24 時間):